Morningstar Investment Services LLC lessened its stake in shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) by 6.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 110,908 shares of the company’s stock after selling 8,185 shares during the quarter. Morningstar Investment Services LLC’s holdings in Takeda Pharmaceutical were worth $1,963,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Coastal Investment Advisors Inc. increased its holdings in Takeda Pharmaceutical by 59.8% in the second quarter. Coastal Investment Advisors Inc. now owns 1,718 shares of the company’s stock valued at $32,000 after buying an additional 643 shares in the last quarter. Shelton Capital Management purchased a new position in shares of Takeda Pharmaceutical in the first quarter valued at $46,000. Advisory Services Network LLC increased its position in shares of Takeda Pharmaceutical by 101.6% in the second quarter. Advisory Services Network LLC now owns 2,076 shares of the company’s stock valued at $37,000 after buying an additional 1,046 shares in the last quarter. Global Retirement Partners LLC increased its position in shares of Takeda Pharmaceutical by 63.3% in the first quarter. Global Retirement Partners LLC now owns 3,421 shares of the company’s stock valued at $70,000 after buying an additional 1,326 shares in the last quarter. Finally, Gabelli Funds LLC raised its stake in shares of Takeda Pharmaceutical by 0.4% during the 2nd quarter. Gabelli Funds LLC now owns 348,712 shares of the company’s stock worth $6,172,000 after buying an additional 1,400 shares during the last quarter. Institutional investors and hedge funds own 9.27% of the company’s stock.

Several equities research analysts recently commented on the stock. Zacks Investment Research lowered shares of Takeda Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Daiwa Capital Markets cut shares of Takeda Pharmaceutical from an “outperform” rating to a “neutral” rating in a research note on Thursday, August 15th. Finally, ValuEngine cut shares of Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, May 15th.

Shares of NYSE:TAK traded up $0.30 during midday trading on Wednesday, reaching $17.37. The company’s stock had a trading volume of 19,394 shares, compared to its average volume of 1,097,884. The firm has a market cap of $26.65 billion, a price-to-earnings ratio of 34.00 and a beta of 0.70. The company’s 50 day moving average is $17.10. Takeda Pharmaceutical Co Ltd has a 1 year low of $15.50 and a 1 year high of $21.95. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.01 and a current ratio of 1.46.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Recommended Story: Economic Reports

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co Ltd (NYSE:TAK).

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.